Press Releases

BrainStorm Cell Therapeutics to Present at Cantor Fitzgerald's Inaugural Healthcare Conference

HACKENSACK, N.J. and PETACH TIKVAH, Israel, July 6, 2015 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that Chief Executive Officer Tony Fiorino, MD, PhD, will present a corporate update at Cantor Fitzgerald's Inaugural Healthcare Conference on Wednesday, July 8 at 4:45 p.m. Eastern Time, at the Le Parker Meridian Hotel in New York, NY.

BrainStorm Cell Therapeutics Inc logo

A webcast will be available during the presentation and may be accessed through the BrainStorm Cell Therapeutics website or directly at  The webcast will be archived and available at that site for 90 days.

About BrainStorm Cell Therapeutics Inc.     
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases. The Company holds the rights to develop and commercialize its NurOwn® technology through an exclusive, worldwide licensing agreement with Ramot, the technology transfer company of Tel Aviv University.  NurOwn® has been administered to over 30 patients with ALS in clinical trials conducted in Israel, and is currently being studied in a randomized, double-blind, placebo-controlled clinical trial in the United States.  For more information, visit the company's website at

Photo -

To view the original version on PR Newswire, visit:

SOURCE BrainStorm Cell Therapeutics Inc.

For further information: Media, Tony Fiorino, MD, PhD, Chief Executive Officer, BrainStorm Cell Therapeutics Inc., 201-488-0460,, Investors, Michael Wood, LifeSci Advisors, LLC, 646-597-6983,
Email Alerts
Investor Contact
Investor FAQs
RSS Feeds